Sanity Group has announced a new distribution partnership with Swiss cannabis operator Astrasana Holding AG, further expanding its footprint in the closely watched Swiss market.
Now a subsidiary of Canadian producer Organigram, following the completion of its €250m acquisition earlier this year, Sanity has signed a new deal with Bogen Pharma GmbH, a subsidiary of Astrasana, to supply its Avaay Medical cannabis products to Swiss patients.
The deal, announced on 15 June, gives Avaay Medical access to Astrasana’s established network of more than 20 Swiss pharmacy partners.
Swiss supply strain
Switzerland’s medical cannabis market currently serves approximately 6,000 patients. While a fraction of the size, it mirrors its German neighbour in the dominance of flower products and the prominence of telemedicine as a growth driver.
However, the gravitational pull of Germany’s meteoric growth has drawn flower supply away from adjacent markets.
According to Astrasana’s Managing Director, Yves Antoniazzi, when the Swiss market also began accelerating meaningfully in 2025, existing supply relationships proved inadequate.
“The strong demand following legalisation in Germany led to supply bottlenecks for many manufacturers, which often made long-term cooperation difficult,’ Antoniazzi said.
“With the Sanity Group and the Avaay Medical product line, we have now found the right partner. The combination of high product quality, professional structures, and reliable delivery capacity gives us the confidence that we can continue to offer our patients in Switzerland a first-class range of products and services.”
Switzerland a ‘key market’
Sanity Group, which is already a key stakeholder in the ongoing Swiss adult-use pilot trials, says Switzerland remains a key strategic and commercial priority.
“Switzerland is a key market for us in Europe, both in terms of medical care and with regard to modern regulatory approaches,” said Leonhard Friedrich, Managing Director of Sanity Group Switzerland.
The deal adds to a footprint in Switzerland that already includes Grashaus Projects, the Sanity Group subsidiary operating two licensed cannabis retail stores in Basel-Landschaft canton as part of an adult-use scientific pilot.
Running since 2023 with 1,800 enrolled participants, approximately 3% of the canton’s adult population, the programme is among the most mature in Europe. Across all eight Swiss pilots, 66% of participants report they no longer source cannabis from illegal channels, according to data presented at the European Cannabis Insights Summit in Berlin last week.
Astrasana Holding AG operates across the full Swiss cannabis value chain, from cultivation and manufacturing to pharmacy distribution, with subsidiaries in Switzerland, the Czech Republic, the UK, and Japan.
The deal forms part of Organigram’s stated ambition, outlined at the time of its Sanity acquisition, to ‘unlock significant growth opportunities as new European markets open to both medical and recreational cannabis programmes.’
Finn Age Hänsel, Co-Founder and CEO of Sanity Group, who remained in post following the acquisition’s completion, spoke at the European Cannabis Insights Summit last week on the policy implications of Swiss pilot data for Germany’s own regulatory trajectory.
